Float Short %

11.07

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

EPS Last/This Y

1.33

EPS This/Next Y

0.64

Price

12.81

Target Price

35.5

Analyst Recom

1.29

Performance Q

-2.66

Relative Volume

0.93

Beta

0.05

Ticker: QURE

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	QURE	9.29	0.15	0.53	38702
2025-04-15	QURE	9.64	0.15	0.14	38817
2025-04-16	QURE	9.41	0.14	0.33	48395
2025-04-17	QURE	12.99	0.13	1.00	48673
2025-04-18	QURE	13	0.13	1.00	48673
2025-04-21	QURE	13.31	0.33	0.30	45102
2025-04-22	QURE	14.38	0.33	0.93	47389
2025-04-23	QURE	14.31	0.33	0.17	47770
2025-04-24	QURE	14.25	0.33	0.81	49143
2025-04-25	QURE	14.18	0.3323227987337	2.4343065693431	49661
2025-04-28	QURE	13.97	0.34073539629095	0.96373056994819	50173
2025-04-29	QURE	13.85	0.35	4.25	50761
2025-04-30	QURE	14.75	0.36	0.80	51951
2025-05-01	QURE	15	0.37	0.55	52641
2025-05-02	QURE	14.77	0.37	0.63	53121
2025-05-05	QURE	15.88	0.37	0.10	53300
2025-05-06	QURE	11.46	0.37	1.41	53289
2025-05-07	QURE	10.05	0.45	0.12	58609
2025-05-08	QURE	12.23	0.41	0.10	63735
2025-05-09	QURE	12.78	0.39	0.07	67957
2025-05-12	QURE	13.15	0.36	0.34	72776
2025-05-13	QURE	12.82	0.36	0.06	74815
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	QURE	9.17	23.9	45.9	-3.71
2025-04-15	QURE	9.65	23.9	38.4	-3.71
2025-04-16	QURE	9.42	23.9	61.0	-3.71
2025-04-17	QURE	13.00	23.9	-58.4	-3.71
2025-04-18	QURE	13.00	23.9	54.2	-3.66
2025-04-21	QURE	13.28	24.6	49.7	-3.66
2025-04-22	QURE	14.39	24.6	37.1	-3.66
2025-04-23	QURE	14.39	25.0	54.2	-3.66
2025-04-24	QURE	14.24	25.0	56.0	-3.66
2025-04-25	QURE	14.18	25.0	55.1	-3.64
2025-04-28	QURE	13.97	25.0	57.1	-3.64
2025-04-29	QURE	13.86	25.0	55.6	-3.64
2025-04-30	QURE	14.76	25.0	43.8	-3.64
2025-05-01	QURE	15.00	25.0	50.8	-3.64
2025-05-02	QURE	14.77	25.7	57.1	-3.61
2025-05-05	QURE	15.89	25.7	39.6	-3.61
2025-05-06	QURE	11.47	25.7	104.9	-3.61
2025-05-07	QURE	10.06	25.7	82.4	-3.61
2025-05-08	QURE	12.24	26.0	-3.1	-3.61
2025-05-09	QURE	12.78	26.0	44.6	-3.59
2025-05-12	QURE	13.15	26.0	48.0	-3.59
2025-05-13	QURE	12.81	26.0	59.5	-3.59
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	QURE	-4.25	7.92	8.88
2025-04-15	QURE	-4.25	7.92	8.88
2025-04-16	QURE	-4.25	7.92	8.88
2025-04-17	QURE	-4.25	7.92	8.88
2025-04-18	QURE	-4.25	7.92	8.88
2025-04-21	QURE	-4.25	9.32	8.88
2025-04-22	QURE	-4.25	9.32	8.88
2025-04-23	QURE	-4.25	9.32	8.88
2025-04-24	QURE	-4.25	9.32	8.88
2025-04-25	QURE	-4.25	9.32	8.88
2025-04-28	QURE	-4.25	9.26	10.63
2025-04-29	QURE	-4.25	9.26	10.63
2025-04-30	QURE	-4.20	9.26	10.50
2025-05-01	QURE	-4.20	9.26	10.50
2025-05-02	QURE	-4.20	9.26	10.50
2025-05-05	QURE	-4.20	9.79	10.50
2025-05-06	QURE	-4.20	9.79	10.50
2025-05-07	QURE	-4.20	9.79	10.50
2025-05-08	QURE	-4.20	9.79	10.50
2025-05-09	QURE	-4.20	9.79	10.50
2025-05-12	QURE	-4.20	10.73	11.07
2025-05-13	QURE	-4.20	10.73	11.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.97

Avg. EPS Est. Next Quarter

-0.95

Insider Transactions

-4.2

Institutional Transactions

10.73

Beta

0.05

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

82.1

Max Drawdown 5-Year %

-94.4

Target Price

35.5

P/E

Forward P/E

PEG

P/S

34.72

P/B

20.8

P/Free Cash Flow

EPS

-4.39

Average EPS Est. Cur. Y

-3.59

EPS Next Y. (Est.)

-2.95

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1077.05

Relative Volume

0.93

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.12

EBIT Estimation

59.5

uniQure N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 209

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

stock quote shares QURE – uniQure N.V. Stock Price stock today

news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch QURE – uniQure N.V. yahoo finance google finance

stock history QURE – uniQure N.V. invest stock market

stock prices QURE premarket after hours

ticker QURE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: QURE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y